businesspress24.com - Agennix AG Schedules Conference Call on March 24, 2010 to Discuss Year-End 2009 Financial Results
 

Agennix AG Schedules Conference Call on March 24, 2010 to Discuss Year-End 2009 Financial Results

ID: 1011675

(Thomson Reuters ONE) -
Agennix AG / Agennix AG Schedules Conference Call on March 24, 2010 to Discuss Year-End 2009 Financial Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, March 22, 2010 -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
hold a conference call to discuss financial results for the fiscal year 2009 and
to provide a business update. The results will be published on March 24, 2010 in
advance of the conference call.



The conference call, which will be conducted in English, will be held on
Wednesday, March 24, 2010 at 2 PM CET/ 9 AM ET.



The live webcast will be available on the Agennix Web site at www.agennix.com. A
replay will be available via the Web site following the live event.



Dial-in numbers for the call are as follows:



Participants from Europe:        0049 (0)69 667775756

0044 (0)20 3003 2666

Participants from the U.S.:       1-646-843-4608



Please dial in 10 minutes before the beginning of the meeting.



About Agennix

Agennix AG is a publicly traded biopharmaceutical company that is developing
novel therapies in areas of major unmet medical need to improve the length and
quality of life of seriously ill patients. The Company's most advanced program
is talactoferrin, an oral targeted therapy that has demonstrated activity in
randomized, double-blind, placebo-controlled Phase 2 studies in non-small cell
lung cancer as well as in severe sepsis. Talactoferrin is currently in Phase 3
clinical trials in non-small cell lung cancer. Other clinical development
programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1




testing; the oral platinum-based compound satraplatin; and a topical gel form of
talactoferrin for diabetic foot ulcers. Agennix's registered seat is in
Heidelberg, Germany. The Company has three sites of operation:
Martinsried/Munich, Germany; Princeton, New Jersey and Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.



This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.



For further information, please contact:




Agennix
AG

Investor Relations & Corporate Communications

Phone: +49 (0)89
8565 2693

ir(at)agennix.com




In the U.S.: Laurie
Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884


laurie.doyle(at)agennix.com






Additional media contacts for Europe:

MC Services
AG

Phone: +49 (0) 89 210 228 0



Raimund
Gabriel

raimund.gabriel(at)mc-services.eu




Hilda
Juhasz

hilda.juhasz(at)mc-services.eu





Additional investor contact for Europe:

Trout International
LLC

Lauren Williams, Vice President

Phone: +44 207 936 9325

lwilliams(at)troutgroup.com




[HUG#1395999]



--- End of Message ---

Agennix AG
Fraunhoferstr. 20 Martinsried Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;







Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Geveko's Swedish Annual Report 2009 released
PROD - Mandatory Notification of Trades
Bereitgestellt von Benutzer: hugin
Datum: 22.03.2010 - 05:43 Uhr
Sprache: Deutsch
News-ID 1011675
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

Martinsried


Phone:

Kategorie:

Business News


Anmerkungen:


Diese Pressemitteilung wurde bisher 124 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Agennix AG Schedules Conference Call on March 24, 2010 to Discuss Year-End 2009 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von

Agennix AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Agennix AG



 

Who is online

All members: 10 586
Register today: 0
Register yesterday: 1
Members online: 0
Guests online: 97


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.